<i>HCK</i> can serve as novel prognostic biomarker and therapeutic target for Breast Cancer patients

Zhu, Xudong; Zhang, Yixiao; Bai, Yang; Gu, Xi; Chen, Guanglei; Sun, Lisha; Wang, Yulun; Qiao, Xinbo; Ma, Qingtian; Zhu, Tong; Bu, Jiawen; Xue, Jinqi; Liu, Caigang

doi:10.7150/ijms.43161



Theranostics

International Journal of Biological Sciences

Nanotheranostics

Journal of Cancer

Journal of Genomics

Global reach, higher impact

Full Text | PDF

Int J Med Sci 2020; 17(17):2773-2789. doi:10.7150/ijms.43161 This issue Cite

Research Paper

HCK can serve as novel prognostic biomarker and therapeutic target for Breast Cancer patients

Xudong Zhu^1#, Yixiao Zhang^1#, Yang Bai^2#, Xi Gu¹, Guanglei Chen¹, Lisha Sun¹, Yulun Wang¹, Xinbo Qiao¹, Qingtian Ma¹, Tong Zhu¹, Jiawen Bu¹, Jinqi Xue¹, Caigang Liu^1✉

1. Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, Liaoning Province, 110004, China.
2. Department of Operating Room, Shengjing Hospital of China Medical University, Shenyang, Liaoning Province, 110004, China.
#These authors contributed equally to this work.

Citation:

Zhu X, Zhang Y, Bai Y, Gu X, Chen G, Sun L, Wang Y, Qiao X, Ma Q, Zhu T, Bu J, Xue J, Liu C. HCK can serve as novel prognostic biomarker and therapeutic target for Breast Cancer patients. Int J Med Sci 2020; 17(17):2773-2789. doi:10.7150/ijms.43161. https://www.medsci.org/v17p2773.htm

Other styles

Abstract

The role of HCK expression in the prognosis of breast cancer patients is unclear. Thus, this study aimed to explore the clinical implications of HCK expression in breast cancer. We assessed HCK expression and genetic variations in breast cancer using Oncomine, GEPIA, UALCAN, and cBioPortal databases. Then, immunochemistry was used to analyze HCK expression in breast cancer specimens, non-cancer tissues and metastatic cancer tissues. Consequently, we evaluated the effect of HCK expression on survival outcomes set as disease-free survival (DFS) and overall survival (OS). Finally, STRING, Coexpedia, and TISIDB database were explored to identify the molecular functions and regulation pathways of HCK. We found that breast cancer tissues have more HCK mRNA transcripts than non-cancer tissues. Patients with HCK expression had significantly shorter DFS and OS. The ratio of HCK expression was higher in cancer tissues than in non-cancer tissues. These results from STRING database, FunRich software, and TISIDB database showed that HCK was involved in mediating multiple biological processes including immune response-regulating signaling pathway, cell growth and maintenance through multiple signaling pathways including epithelial to mesenchymal transition, PI3K/AKT signaling pathway, and focal adhesion. Overall, HCK may be an oncogene in the development of breast cancer and thus may as a novel biomarker and therapeutic target for breast cancer.

Keywords: breast cancer, HCK, prognosis, biomarker, bioinformatic

Citation styles

APA

Zhu, X., Zhang, Y., Bai, Y., Gu, X., Chen, G., Sun, L., Wang, Y., Qiao, X., Ma, Q., Zhu, T., Bu, J., Xue, J., Liu, C. (2020). HCK can serve as novel prognostic biomarker and therapeutic target for Breast Cancer patients. International Journal of Medical Sciences, 17(17), 2773-2789. https://doi.org/10.7150/ijms.43161.

ACS

Zhu, X.; Zhang, Y.; Bai, Y.; Gu, X.; Chen, G.; Sun, L.; Wang, Y.; Qiao, X.; Ma, Q.; Zhu, T.; Bu, J.; Xue, J.; Liu, C. HCK can serve as novel prognostic biomarker and therapeutic target for Breast Cancer patients. Int. J. Med. Sci. 2020, 17 (17), 2773-2789. DOI: 10.7150/ijms.43161.

NLM

CSE

Zhu X, Zhang Y, Bai Y, Gu X, Chen G, Sun L, Wang Y, Qiao X, Ma Q, Zhu T, Bu J, Xue J, Liu C. 2020. HCK can serve as novel prognostic biomarker and therapeutic target for Breast Cancer patients. Int J Med Sci. 17(17):2773-2789.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.